WINCHESTER, MA – Wise Construction announced that it has completed Foghorn Therapeutics’ 60,000-SF headquarters in Kendall Square in Cambridge, MA.
Located at 500 Technology Square, the new lab and office facility for Foghorn Therapeutics spans more than 60,000-SF over three floors. The project was completed in two phases on an accelerated schedule.
The successful completion of the project was driven by a 3D model of the space developed by Wise Construction’s in-house Virtual Design & Construction/BIM team. The model accounted for existing conditions and the current building systems. This information was critical in the planning of the project, ensuring that ceiling heights were maximized while aligning the new lab and office supply and exhaust systems with the existing base building systems.
The project incorporated prefabricated duct work, pipe racks, and plumbing racks, helping to execute a more efficient schedule. When construction came to a stop in March due to Covid-19, these schedule efficiencies became even more critical. Despite the Covid-19 impacts, Wise was still able to bring the project in with a 5% reduction in the schedule’s duration with phase two being completed a month ahead of the original projected date.
As Foghorn Therapeutics continues to grow, raising $135 million in its IPO debut in October of 2020, the new headquarters provides a space for its team to flourish. The expanded biology and chemistry labs will support the company’s continued mission to pioneer a new class of precision therapies in oncology and beyond and Wise Construction is proud to have had a small part in that.
The Foghorn Therapeutics Team Included: Alexandria Real Estate Equities, CBRE, Tria, R.W. Sullivan & Code Red Consultants.
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control ® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.